MN HF1847

Health plan companies cannot require higher co-payments, deductibles, or coinsurance for orally administered anticancer medications compared to intravenously administered or injected cancer medications.

Health plans must treat orally administered anticancer medications the same as intravenously administered chemotherapy medications regardless of formulation or how the health plan categorizes the benefit.

Health plans cannot increase co-payment, deductible, or coinsurance amounts for intravenously administered cancer chemotherapy agents to achieve compliance with this requirement.

Prior authorization and other appropriate utilization controls remain permitted for all chemotherapy medications under the requirement.

Provisions take effect August 1, 2010 for health plans covering Minnesota residents, with the restriction on increasing intravenous chemotherapy costs effective upon final enactment.